Esophageal neuroendocrine carcinoma complicated with unexpected hyperprocalcitonin : Case report and literature review
RATIONALE: Neuroendocrine tumors (NETs) with hyperprocalcitonin are relatively rare with a low incidence rate.
PATIENT CONCERNS: An afebrile 63-year-old male with persistent low back pain unexpectedly presented with an extreme hyperprocalcitonin. Radiological assessment revealed thickening of the esophageal wall with vertebral bone destruction and liver lesions. Endoscopy showed an irregular-shaped esophageal lesion which turned out to be poorly-differentiated NETs.
DIAGNOSIS: Esophageal NETs with multiple metastases.
INTERVENTIONS: The patient was treated with chemotherapies, and was evaluated by procalcitonin level and radiology within follow-up.
OUTCOME: The procalcitonin levels were altered in line with the therapeutic response and disease progression during the treatment course.
LESSONS: Increased procalcitonin occurs in several malignancies with neuroendocrine components, such as NETs of the digestive system.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
Medicine - 97(2018), 40 vom: 10. Okt., Seite e12219 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Qida [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.10.2018 Date Revised 05.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000012219 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289259525 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289259525 | ||
| 003 | DE-627 | ||
| 005 | 20231225062147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000012219 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0964.xml |
| 035 | |a (DE-627)NLM289259525 | ||
| 035 | |a (NLM)30290592 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Qida |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Esophageal neuroendocrine carcinoma complicated with unexpected hyperprocalcitonin |b Case report and literature review |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2018 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a RATIONALE: Neuroendocrine tumors (NETs) with hyperprocalcitonin are relatively rare with a low incidence rate | ||
| 520 | |a PATIENT CONCERNS: An afebrile 63-year-old male with persistent low back pain unexpectedly presented with an extreme hyperprocalcitonin. Radiological assessment revealed thickening of the esophageal wall with vertebral bone destruction and liver lesions. Endoscopy showed an irregular-shaped esophageal lesion which turned out to be poorly-differentiated NETs | ||
| 520 | |a DIAGNOSIS: Esophageal NETs with multiple metastases | ||
| 520 | |a INTERVENTIONS: The patient was treated with chemotherapies, and was evaluated by procalcitonin level and radiology within follow-up | ||
| 520 | |a OUTCOME: The procalcitonin levels were altered in line with the therapeutic response and disease progression during the treatment course | ||
| 520 | |a LESSONS: Increased procalcitonin occurs in several malignancies with neuroendocrine components, such as NETs of the digestive system | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Calcitonin |2 NLM | |
| 650 | 7 | |a 9007-12-9 |2 NLM | |
| 700 | 1 | |a Jin, Piaopiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Wangteng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Bingfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Shiyi |e verfasserin |4 aut | |
| 700 | 1 | |a Que, Risheng |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Tingbo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 97(2018), 40 vom: 10. Okt., Seite e12219 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2018 |g number:40 |g day:10 |g month:10 |g pages:e12219 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000012219 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2018 |e 40 |b 10 |c 10 |h e12219 | ||